These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 22154023)
21. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692 [TBL] [Abstract][Full Text] [Related]
22. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738 [TBL] [Abstract][Full Text] [Related]
23. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K; Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007 [TBL] [Abstract][Full Text] [Related]
24. Bendamustine: a new treatment option for chronic lymphocytic leukemia. Glode AE; Jarkowski A Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152 [TBL] [Abstract][Full Text] [Related]
25. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497 [TBL] [Abstract][Full Text] [Related]
26. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia. Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444 [TBL] [Abstract][Full Text] [Related]
27. Bendamustine (Treanda) for CLL and NHL. Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789 [No Abstract] [Full Text] [Related]
36. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Malipatil B; Ganesan P; Sundersingh S; Sagar TG Hematol Oncol Stem Cell Ther; 2011; 4(4):157-60. PubMed ID: 22198186 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Corazzelli G; Angrilli F; D'Arco A; Ferrara F; Musto P; Guarini A; Cox MC; Stelitano C; Storti S; Iannitto E; Falorio S; Califano C; Amore A; Arcamone M; De Filippi R; Pinto A Br J Haematol; 2013 Jan; 160(2):207-15. PubMed ID: 23167437 [TBL] [Abstract][Full Text] [Related]
38. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124 [TBL] [Abstract][Full Text] [Related]
39. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722 [TBL] [Abstract][Full Text] [Related]
40. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]